bluebird bio (NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations ...

Fintel reports that on August 15, 2024, JP Morgan downgraded their outlook for bluebird bio (MUN:BLE) from Overweight to Neutral. As of December 21, 2023, the average one-year price target for ...

On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents. The gene therapy company ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that Ivan Dimov, ...

Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...

Standard BioTools Inc. announced that its President and CEO, Dr. Michael Egholm, will present at the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2024, with his presentation ...